Oligonucleotide-based Therapies: An Innovation for Neurodegenerative disorders
Oligonucleotides are short chain RNA or DNA typically made by using automated synthesizers. Oligonucleotides therapy is different from conventional medicine since it can inhibit the expression of specific genes and their development takes place with the raw chemical modified artificial nucleus acids. This lead to development of brand new oligonucleotides targeting certain genes and treating chronic diseases. They are broadly used in applications such as infectious diseases, oncology, kidney diseases, and cardiovascular diseases.
Get the detailed inside story here: https://www.reportsweb.com/inquiry&RW00014327632/sample?source=shikha
Drivers - Increasing incidence of cancer and infectious disease and the necessity for personalized medicines for neurodegenerative disorders is expected to drive the oligonucleotide-based therapies market. - Increasing demand for novel therapies and growing innovative new oligonucleotides boosts the market growth. - Rising licensing and collaboration activities and growing demand for advanced technologies in oligonucleotide therapeutics fuel the market
Analysis By Type (Antisense, Ribozymes, Aptamers, Mirna, CPG/Immunostimulatory, RNAi.); Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others.)












